Mereo BioPharma Group plc (MREO)
About Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $500.0K
- Net income
- -$41.9M
- Total assets
- $45.9M
- Market cap
- $50.0M
- Operating margin
- -8021.4%
- Net margin
- -8375.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $500.0K
- Operating expenses
- $40.6M
- Operating income
- -$40.1M
- Income tax
- $0
- Net income
- -$41.9M
- EPS (basic)
- $-0.05
- EPS (diluted)
- $-0.05
Balance sheet
- Total assets
- $45.9M
- Current assets
- $45.0M
- Total liabilities
- $5.0M
- Current liabilities
- $4.3M
- Shareholders’ equity
- $40.9M
Cash flow
- Operating cash flow
- -$31.0M
- Investing cash flow
- -$20.0K
- Financing cash flow
- $327.0K
- Net cash flow
- -$28.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $50.0M
- EPS (diluted)
- $-0.05
- Shares outstanding
- 172.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 24, 2018
Mereo BioPharma Group plc (MREO) Stock Price
- Reported a net loss of $41.9M in FY2025.
- Revenue declined 95% from FY2023 to FY2025.
- Trading 90% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Mereo BioPharma Group plc.
Write a review
News about Mereo BioPharma Group plc
News & sentiment via Polygon.io
Mereo BioPharma Group plc: frequently asked questions
Is Mereo BioPharma Group plc an American company?
Mereo BioPharma Group plc is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Mereo BioPharma Group plc publicly traded?
Yes — Mereo BioPharma Group plc is a publicly traded company. Its stock trades under the ticker symbol MREO on the NASDAQ.
What does Mereo BioPharma Group plc do?
Mereo BioPharma Group plc is an American Pharmaceuticals company in the Health & Beauty sector.
